Black Diamond Therapeutics, Inc.
3 clinical trials · Sponsor
◉ Watch Black Diamond Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII (NCT07326566) | Black Diamond Therapeutics, Inc. | 2026-05-05 |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations (NCT05256290) | Black Diamond Therapeutics, Inc. | 2022-03-31 |
| A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. (NCT04209465) | Black Diamond Therapeutics, Inc. | 2019-12-19 |
Track Black Diamond Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.